Beta Thalassaemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Beta Thalassaemia – Drugs In Development, 2024 report and make more profitable business decisions.
Beta-thalassemia is a genetic blood disorder characterized by reduced or absent production of beta-globin chains, a component of hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. This deficiency leads to anemia and various complications. Beta-thalassemia is classified based on the severity of symptoms: In beta-thalassemia major (Cooley’s anemia), individuals have little or no beta-globin production, leading to severe anemia, pale skin, fatigue, bone deformities, enlarged spleen, jaundice, and growth problems. Beta-thalassemia intermedia is less severe than major but can still cause moderate to severe anemia and various complications. Beta-thalassemia is an autosomal recessive genetic disorder, meaning an affected individual must inherit two abnormal beta-globin genes (one from each parent). Carriers of one abnormal gene (thalassemia trait) generally do not have symptoms but can pass the defective gene to their children.
The Beta Thalassaemia drugs in development market research report provide comprehensive information on the therapeutics under development for Beta Thalassaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Beta Thalassaemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Beta Thalassaemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 58 molecules, with 52 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Beta Thalassaemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Beta Thalassaemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Beta Thalassaemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abfero Pharmaceuticals IncAgios Pharmaceuticals Inc
Allife Medical Science and Technology Co Ltd
Ariya Bio
ASC Therapeutics Inc
Ascentage Pharma Group Inc
Beam Therapeutics Inc
Bellicum Pharmaceuticals Inc
Biomac Lifesciences Pvt Ltd
BRL Medicine Inc
Cell Source Inc
Centre for Stem Cell Research
Cetya Therapeutics Inc
CHA Biotech Co Ltd
CorrectSequence Therapeutics Co Ltd
CRISPR Therapeutics AG
CSL Ltd
Disc Medicine Inc
EdiGene Inc
Editas Medicine Inc
Garuda Therapeutics Inc
Genmedicn Biopharma Ltd
Guangzhou Reforgene Medicine Co Ltd
ImmuneCyte Inc
Invenux LLC
Jasper Therapeutics Inc
Jazz Pharmaceuticals Plc
Kanglin Biotech Hangzhou Co Ltd
Mabwell Therapeutics Inc
Merck & Co Inc
Merganser Biotech Inc
Mina Therapeutics Ltd
Monte Rosa Therapeutics Inc
Nanfang Hospital
Novartis AG
Novo Nordisk AS
Orchard Therapeutics Plc
Phoenicia Biosciences Inc
Prolong Pharmaceuticals LLC
Rallybio Corp
Rare Partners Srl
Regenacy Pharmaceuticals LLC
San Rocco Therapeutics LLC
Sana Biotechnology Inc
Shanghai BDgene Therapeutics Co Ltd
Shanghai Vitalgen BioPharma Co Ltd
Shenzhen Geno-Immune Medical Institute
Shenzhen Hemogen Gene Biotechnology Co Ltd
Silence Therapeutics Plc
Suzhou GenAssist Therapeutics Co Ltd
Syros Pharmaceuticals Inc
U.S. National Institutes of Health
University of Oxford
Vertex Pharmaceuticals Inc
Vifor Pharma Management Ltd
Weill Cornell Medical College
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Beta Thalassaemia reports